Valacyclovir Tablet, Film Coated
Product Images NDC 61919-066

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Valacyclovir (NDC 61919-066). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Direct Rx, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image Description (Label)

This is a product description of Valacyclovir, a medication used to treat herpes virus infections. It comes as a 500mg tablet and is sold in a bottle of 60 tablets. There are details about the drug including the active ingredient, Valacyclovir Hydrochloride, which is USP equivalent to Valacyclovir 500mg. The package has a lot expiration date, although the text is not clear. The drug is meant for prescription only and customers are advised to keep it out of reach of children. Specific dosage instructions are not provided, so customers should consult with their physicians.*

FDA Label Image

Image Description (Molecule)

Valacyclovir hydrochloride is a medication available in the form of white to off-white powder. Its molecular formula is Cy3HoNeOz+HCL, and it has a maximum solubility of 174 mg/mL in water at 25°C. The pKss for the medication are 1.90, 7.47, and 9.43.*

FDA Label Image

Image Description (Table2)

FDA Label Image

Image Description (Table3)

This text appears to be a chart comparing the effectiveness of Valacyclovir (a medication commonly used to treat herpes) versus a placebo. It includes information on dosages, frequency of administration, and various laboratory abnormalities observed in test subjects. No other information or context is provided.*

FDA Label Image

Image Description (Table4)

This text appears to be a table presenting the results of a study regarding the suppression of genital herpes with the use of Valacyclovir and Placebo. The table displays the number of participants in each group, dosages given, and percentages of occurrences. Without further context, it is difficult to provide more information.*

FDA Label Image

Image Description (Table5)

This appears to be a tabular format of data with variable dosages administered as single-dose and multiple-dose administration. The data seems to contain measurements of Crsx, AUC, and Cansx at different time points and treatment arms for each dosage. However, it is difficult to interpret the data without additional information on the subject matter.*

FDA Label Image

Image Description (Table6)

FDA Label Image

Image Description (Table7)

FDA Label Image

Image Description (Table8)

This text presents the outcome of a study comparing the efficacy of Valacyclovir Hydrochloride versus placebo in preventing recurrences of a certain condition. The study involved 99 participants who received 500 mg of Valacyclovir Hydrochloride twice daily and 194 participants who received a placebo. The results showed that the Valacyclovir Hydrochloride group had a recurrence-free rate of 65% compared to the placebo group that had only 26%. Recurrences occurred in 17% of the Valacyclovir Hydrochloride group and 57% of the placebo group, while 18% of the Valacyclovir Hydrochloride group and 17% of the placebo group had unknown outcomes.*

FDA Label Image

Image Description (Table9)

The text provides a table showing the percentage of susceptible partners who acquired the HSV-2 virus after being administered Valacyclovir® or Placebo. The table shows the results for three different endpoints, namely Symptomatic HSV-2 acquisition, HSV-2 seroconversion, and Overall HSV-2 acquisition, with corresponding percentages for both Valacyclovir® and Placebo.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.